Super Micro Computer Inc’s new production facilities in Taoyuan’s Bade District (八德) would next month start producing servers, workstations and networking equipment, company founder and chairman Charles Liang (梁見後) said yesterday.
Taiwanese-born Liang founded Super Micro in California, but decided to return part of the firm’s production facilities to Taiwan.
“I’m familiar with Taiwan [and] aware of the excellent talent available and good conditions provided by the government,” Liang said in a virtual speech at the annual Computex Taipei trade show. “We have more than 2,000 employees here in Taiwan, second only to our headquarters in Silicon Valley.”
Photo courtesy Super Micro Computer Inc
“We’ve been expanding our presence in Taiwan’s technology parks from production to logistics so that we can become more and more competitive,” Liang said, adding that the parks have “the end-to-end production capabilities we need to go from production to certification on a single campus.”
The facility in Taoyuan would comprise five new buildings with a total of 280,000m2 floor space
Super Micro, which also produces products in Silicon Valley and the Netherlands, aims to assemble 2 million systems per year.
However, a semiconductor shortage would influence the expansion, Liang said.
Super Micro would in the next few month increase prices due to higher production costs, he said, calling the price hike a “reasonable way to share costs between producer and customers.”
The month-long Computex started on Monday, featuring 221 businesses from 34 countries. It is the second year that the event has been held virtually due to the COVID-19 pandemic.
Taiwan and China are to build more new high-volume semiconductor fabrication plants this year and next year than any other country, together contributing more than half of all new fabs in the world by constructing eight each, SEMI said in a quarterly report yesterday. Global chipmakers are to start building 19 new high-volume fabs by the end of this year and another 10 next year to meet accelerating demand for chips from the communications, computing, healthcare, online services and automotive sectors, SEMI, an association that represents the global semiconductor sector, said in its quarterly report. “Equipment spending for these 29 fabs is
Major PC vendors expect a shortage of key components to last another 12 months until the second quarter of next year, when PC demand wanes after two years of robust expansion, a UBS analyst said yesterday. Concern has risen among investors that PC demand could weaken as the US and European economies reopen from COVID-19 lockdowns and gradually return to in-person business activities. At the annual Taiwan Conference that began on Monday, UBS analysts said they had similar discussions with companies in PC supply chains, and the feedback from major PC vendors indicated that demand remained quite strong on the back of
QUICK CHANGE: After a prolonged drought, the Water Resources Agency said it is preparing for potential floods from intense rainfall this week The Ministry of Economic Affairs yesterday announced that it was easing water restrictions in several regions, thanks to rainfall over the past few days. The water supply alert level has been downgraded from “orange” to “yellow” for Taoyuan and Hsinchu and Miaoli counties, and from “orange” to “green” for Tainan and Chiayi County, the ministry said. Only Taichung remains under “orange” alert, with round-the-clock decreased water pressure, it said. A combination of water management measures and considerable plum rains and tropical showers has seen reservoirs significantly replenished across the nation, Minister of Economic Affairs Wang Mei-hua (王美花) said. Just weeks ago water levels
OPPORTUNITY: The company aims to sell its product soon, as enterovirus vaccines are not available anywhere but China, where firms are only marketing their vaccines locally Medigen Vaccine Biologics Corp’s (高端疫苗) phase 3 clinical trials for an enterovirus 71 (EV71) vaccine completed the multi-regional, multi-central data “unblinding” yesterday, with the results, including safety, immunogenicity and efficacy, meeting its expectations. The company would compile a final analysis report as soon as possible, and apply for the new drug certificate from domestic and foreign drug authorities in the third quarter, Medigen said in a Taiwan Stock Exchange filing yesterday. Its phase 3 trials were conducted in Taiwan and Vietnam with 3,049 participants ranging from two months old to six years old, Medigen said. The company enrolled its first participant for